Abstract
T cell-engaging immunotherapies are changing the therapeutic landscape of cancer. However, suitable target antigens are scarce, restricting these strategies to very few tumor types. To overcome this limitation, we developed a T cell-engaging antibody derivative, which comes in two complementary halves and addresses antigen combinations instead of single molecules. Each half, originally coined hemibody, contains an antigen specific single-chain variable fragment fused to either the variable light (VL) or variable heavy (VH) chain domain of an anti-CD3 antibody.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
